# Dyadic International (DYAI) — News

DYAI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/dyai/news

## Recent headlines

- [Dyadic announces second quarter 2026 financial results accelerating commercialization momentum across key business areas](https://www.ainvest.com/news/dyadic-announces-quarter-2026-financial-results-accelerating-commercialization-momentum-key-business-areas-2608) — AInvest Wire, Aug 12, 2026
  Dyadic International, Inc. (Nasdaq: DYAI) announced today that it will release its financial results for the second quarter ended June 30, 2026, and host a conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. The company, which specializes in the production of high-value…
- [Dyadic Intl Inc.: Dyadic expands commercial non-animal dairy pipeline through new strategic development pact](https://www.ainvest.com/news/dyadic-intl-dyadic-expands-commercial-animal-dairy-pipeline-strategic-development-pact-2608) — AInvest Wire, Aug 4, 2026
  Dyadic International, Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, has expanded its commercial pipeline for non-animal dairy enzymes through a new strategic development agreement. The company announced the planned 2026 commercialization of a recombinant non-animal bovine chymosin,…
- [Dyadic International - regains compliance with Nasdaq listing rules 5550(a)(2) and 5550(b)](https://www.ainvest.com/news/dyadic-international-regains-compliance-nasdaq-listing-rules-5550-2-5550-2607) — AInvest Wire, Jul 24, 2026
- [Dyadic announces continued listing on the Nasdaq Capital Market](https://www.ainvest.com/news/dyadic-announces-continued-listing-nasdaq-capital-market-2607) — AInvest Wire, Jul 24, 2026
- [Dyadic International - to pursue multiple commercialization pathways for new enzyme program](https://www.ainvest.com/news/dyadic-international-pursue-multiple-commercialization-pathways-enzyme-program-2607) — AInvest Wire, Jul 16, 2026
  Dyadic International, Inc. (NASDAQ: DYAI) has outlined plans to pursue multiple commercialization pathways for its new enzyme program, reflecting its ongoing efforts to expand its portfolio of animal-free proteins and enzymes. The company has entered into several strategic agreements and…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).